Glucose-Sensitive Drug Conjugates for Hypoglycemia Prevention
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current insulin therapies for type 2 diabetes lack a glucose-sensitive release mechanism, leading to challenges in managing blood glucose levels and preventing hypoglycemia, as they do not mimic the natural glucose-dependent insulin release by the pancreas.
Innovation Solution
Development of novel conjugates comprising a pharmaceutical agent, such as insulin or insulinotropic peptides, linked with a sugar moiety that binds to the insulin-independent glucose transporter GluT1, allowing for glucose-dependent release and recapture, thereby mimicking natural insulin release patterns.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If non-glucose-sensitive depots are used to protect drugs and elongate half-life, then drug protection and half-life extension are improved, but glucose-dependent release capability deteriorates
Solution Approach 1:
The invention transforms static, non-responsive depots into dynamic systems that automatically adjust drug release based on glucose concentration. The glucose-sensitive moiety acts as a molecular switch that changes the binding affinity between the depot and drug in response to glucose levels, enabling the depot to transition between bound and unbound states according to physiological needs.
Solution Approach 2:
The invention changes the binding parameter (affinity) of the depot-drug complex in response to glucose concentration changes. When glucose levels rise, the binding affinity decreases, triggering drug release. When glucose levels fall, binding affinity increases, allowing drug recapture. This parameter change mechanism enables glucose-responsive control while maintaining prolonged circulation.
2Reliability
If flat insulin profiles are used to counteract hypoglycemia risk, then hypoglycemia prevention is improved, but glucose-responsive insulin release deteriorates
Solution Approach 1:
The invention implements a negative feedback mechanism where elevated glucose levels trigger insulin release, which in turn lowers glucose levels, causing the system to recapture and store insulin. This closed-loop feedback mimics physiological pancreatic function, providing reliable hypoglycemia prevention while maintaining glucose-responsive release.
3Ease of operation
If static depots are used for controlled insulin release, then release control is improved, but glucose-sensitivity deteriorates
Solution Approach 1:
The invention introduces a glucose-sensitive moiety as an intermediary between the static depot structure and the drug molecule. This intermediary component transduces glucose concentration changes into binding affinity changes, enabling the static depot to achieve dynamic, glucose-sensitive insulin release without compromising structural simplicity or control.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The conjugates provide a glucose-sensitive delivery system that maintains stable blood glucose levels by releasing the pharmaceutical agent only when glucose concentrations are elevated, reducing the risk of hypoglycemia and improving glycemic control.
Implementation Method 1
a sugar moiety that binds to the insulin-independent glucose transporter GluT1
Implementation Method 2
releasing the pharmaceutical agent only when glucose concentrations are elevated
Data Source
AI summary
The invention describes novel conjugates of formula (I) of a pharmaceutical agent and a moiety capable of binding to a glucose sensing protein allowing a reversible release of the pharmaceutical agent depending on the glucose concentration.